Congressional Approval Of PATH Act Would Show U.S. Commitment To Addressing Antimicrobial Resistance

The Hill: World leaders take notice, clock is ticking on antibiotics
William G. Powderly, president of the Infectious Diseases Society of America

“Earlier this fall, the United Nations General Assembly met to declare a commitment to addressing the public health crisis of antimicrobial resistance. World leaders recognized that nations must act quickly and aggressively to combat drug-resistance and spur antibiotic research and development. The U.S. Senate can make an immediate and important contribution to this effort by passing the bipartisan Promise for Antibiotics and Therapeutics for Health (PATH) Act. … The PATH Act … would establish a new limited population approval pathway at the FDA for antibiotics that treat often life-threatening infections for which there exists an unmet medical need. … [A]ntimicrobial resistance must be treated with a sense of urgency. … Congressional approval of the PATH Act prior to adjourning for the year would demonstrate recognition that lives are on the line and that our nation is capable of exercising leadership to address the crisis” (11/8).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.